Palonosetron

Generic Name: Palonosetron

Brand Names: Akynzeo, Aloxi, Palonosetron Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₄N_₂O

CAS Number: 135729-56-5

Unique Ingredient Identifier: 5D06587D6R

Background: Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

Indication: For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.

Associated Conditions: Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting

Clinical Trials

Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP

Phase 4

Conditions: Postoperative Nausea and Vomiting
Antiemetic

Interventions: Drug: Palonosetron 75 mcg
Drug: Ondansetron 4 mg

First Posted Date: 2020-10-06

Last Posted Date: 2020-10-06

Lead Sponsor: Theodor Bilharz Research Institute

Target Recruit Count: 90

Registration Number: NCT04576390

Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female

Not Applicable

Completed

Conditions: Gallbladder Diseases

Interventions: Drug: Normal saline injection
Drug: Palonosetron Injection [Aloxi]

First Posted Date: 2020-09-24

Last Posted Date: 2021-05-11

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 45

Registration Number: NCT04563260

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea, Republic of

Palonosetron vs. Ondansetron for Postoperative Nausea and Vomiting in Bariatric Surgery

Completed

Conditions: Pain, Postoperative
Patient Reported Outcomes
Vomiting, Postoperative
Antiemetics
Nausea, Postoperative

Interventions: Procedure: Laparoscopic sleeve gastrectomy
Drug: Ondansetron 1 mg/kg, max dose 8 mg
Drug: Palonosetron 1mcg/kg

First Posted Date: 2020-09-01

Last Posted Date: 2021-01-22

Lead Sponsor: Bagcilar Training and Research Hospital

Target Recruit Count: 100

Registration Number: NCT04533867

Locations: 🇹🇷
Bagcılar Training and Research Hospital, Istanbul, Turkey
🇹🇷
Surp Pırgic Armenian Hospital, Istanbul, Turkey

A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation

Phase 2

Recruiting

Conditions: Gastric Cancer
Stomach Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Palonosetron
Radiation: 3D conformal or intensity modulated radiotherapy
Procedure: Surgical resection
Radiation: Adjuvant Chemotherapy

First Posted Date: 2020-03-16

Last Posted Date: 2023-11-14

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 29

Registration Number: NCT04308837

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai St. Luke's, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States